Study On Haploidentical Transplantation For Treatment Of Murine Solid Hepatoma 22

In the last two decades, various immunological strategies have been assessed to stimulate antitumor immunity in cancer patients. In this field, there is a growing perception that the graft-versus-leukemia (GVL) reaction induced by allogeneic hematopoietic stem cell transplantation (HSCT) is the most potent form of cancer immunotherapy in current clinical use, and that the donor lymphocyte infusion (DLI) following HSCT induces effective graft-versus-tumor responses in patients with posttransplantation leukemic relapse. Allogeneic hematopoietic stem cell transplantation is currently being used as a therapy for hematological malignancies and some solid tumors. Nevertheless, its clinical applicability is limited due to toxicity of conditioning regimens, graft-versus-host disease (GVHD) and the scarcity of HLA-identical family donors. Laying the foundation for the development of novel immunotherapeutic strategies, new concepts are based on nonmyeloablative conditioning to reduce toxicity, prevention or amelioration of GVHD and the use of haploidentical donors to increase donor availability. Yet the application of this approach is still limited due to the treatment-related complications, transplant-related mortality (TRM), and recurrent malignancy. In the near future the major challenge for investigators in this field will be how to maximize the GVT effect while avoid or minimize GVHD.In this study, the effects of graft-versus-tumor (GVT) induced by the allogeneic...